12 hours Ago By Defense World Staff
MRP Capital Investments LLC trimmed its stake in shares of Eli Lilly and Company ( NYSE:LLY – Free Report ) by 5.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,955 shares of the company’s stock after selling 175 shares during the period.
Eli Lilly and Company comprises about 2.5% of MRP Capital Investments LLC’s holdings, making the stock its 7th biggest holding. MRP Capital Investments LLC’s holdings in Eli Lilly and Company were worth $2,675,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors have also modified their holdings of LLY. Tidemark LLC purchased a new position in Eli Lilly and Company during the 4th quarter worth approximately $29,000. Core Wealth Advisors Inc.
boosted its position in shares of Eli Lilly and Company by 188.2% in the fourth quarter. Core Wealth Advisors Inc.
now owns 49 shares of the company’s stock worth $29,000 after buying an additional 32 shares during the period. Lynx Investment Advisory purchased a new position in shares of Eli Lilly and Company during the second quarter valued at $32,000. LGT Financial Advisors LLC acquired a new position in Eli Lilly and Company during the second quarter valued at $36,000.
Finally, Frank Rimerman Advisors LLC purchased a new stake in Eli Lilly and Company in the 4th quarter worth about $37,000. Institutional investors and hedge funds own 82.53% of the company’s stock.
Eli Lilly and Company Price Performance NYSE:LLY opened at $905.10 on Thursday. The company has a debt-to-equity ratio of 1.
74, a current ratio of 1.11 and a quick ratio of 0.87.
Eli Lilly and Company has a one year low of $516.57 and a one year high of $972.53.
The company has a fifty day moving average price of $896.00 and a 200 day moving average price of $836.45.
The stock has a market cap of $860.21 billion, a P/E ratio of 133.30, a PEG ratio of 2.
79 and a beta of 0.42. Eli Lilly and Company Announces Dividend The company also recently announced a quarterly dividend, which was paid on Tuesday, September 10th.
Investors of record on Thursday, August 15th were paid a $1.30 dividend. The ex-dividend date of this dividend was Thursday, August 15th.
This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.57%.
Eli Lilly and Company’s payout ratio is 76.58%. Wall Street Analyst Weigh In A number of research analysts recently commented on the stock.
Morgan Stanley reaffirmed an “overweight” rating and set a $1,106.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, August 27th. Bank of America raised their price target on Eli Lilly and Company from $1,000.
00 to $1,125.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Citigroup started coverage on Eli Lilly and Company in a research note on Friday, September 13th.
They issued a “buy” rating and a $1,060.00 price target for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $885.
00 price objective on shares of Eli Lilly and Company in a research report on Monday. Finally, BMO Capital Markets lifted their target price on shares of Eli Lilly and Company from $1,001.00 to $1,101.
00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat.
com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $977.35. Check Out Our Latest Analysis on Eli Lilly and Company Insider Activity at Eli Lilly and Company In other news, major shareholder Lilly Endowment Inc sold 17,229 shares of the stock in a transaction on Monday, June 24th.
The shares were sold at an average price of $902.38, for a total value of $15,547,105.02.
Following the completion of the transaction, the insider now owns 97,556,910 shares in the company, valued at approximately $88,033,404,445.80. The sale was disclosed in a filing with the SEC, which is available at this link .
Over the last ninety days, insiders sold 442,229 shares of company stock worth $410,002,456. 0.13% of the stock is owned by corporate insiders.
About Eli Lilly and Company ( Free Report ) Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. Featured Stories Five stocks we like better than Eli Lilly and Company Why Are Stock Sectors Important to Successful Investing? 3 Beaten-Down Stocks Ready for a Comeback 3 Must-Buy Warren Buffett Stocks for Volatile Times 3 Stocks to Neutralize Market Volatility and Build Wealth How to Invest in Small Cap Stocks How Much Can You Make in Stocks in One Month? Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Eli Lilly and Company ( NYSE:LLY – Free Report ). Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter .
.
